Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 8Prostatic Neoplasms 7Ovarian Neoplasms 6Breast Neoplasms 6Carcinoma, Transitional Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Neoplasms 3Neoplasm Metastasis 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Tumor Virus Infections 1Thrombocytosis 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrent Bladder Urothelial Carcinoma 1Recurrence 1

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Albumin-Bound Paclitaxel × Genitourinary × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡